このエントリーをはてなブックマークに追加
ID 57821
フルテキストURL
著者
Miyoshi, Yuichiro Department of Breast and Endocrine Surgery, Okayama University Hospital
Shien, Tadahiko Department of Breast and Endocrine Surgery, Okayama University Hospital ORCID Kaken ID publons
Ogiya, Akiko Department of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
Ishida, Naoko Department of Breast Surgery, Hokkaido University Hospital
Yamazaki, Kieko Department of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
Horii, Rie Division of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research
Horimoto, Yoshiya Department of Breast Oncology, Juntendo University School of Medicine
Masuda, Norikazu Department of Surgery, Breast Oncology, NHO Osaka National Hospital
Yasojima, Hiroyuki Department of Surgery, Breast Oncology, NHO Osaka National Hospital
Inao, Touko Department of Breast and Endocrine Surgery, Graduate School of Medical Science Kumamoto University
Osako, Tomofumi Department of Breast and Endocrine Surgery, Kumamoto City Hospital
Takahashi, Masato Department of Breast Surgery, NHO Hokkaido Cancer Center
Tomioka, Nobumoto Department of Breast Surgery, NHO Hokkaido Cancer Center
Wanifuchi‑Endo, Yumi Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences
Hosoda, Mitsuchika Department of Breast Surgery, Hokkaido University Hospital
Doihara, Hiroyoshi Department of Breast and Endocrine Surgery, Okayama University Hospital
Yamashita, Hiroko Department of Breast Surgery, Hokkaido University Hospital
抄録
The value of assessing tumor infiltrating lymphocytes (TILs) in estrogen receptor (ER) positive/human epidermal growth factor receptor type 2 (HER2) negative breast cancer has yet to be determined. In the present study, a total of 184 cases with early distant recurrence detected within 5 years following the primary operation, 134 with late distant recurrence diagnosed following 5 years or longer and 321 controls without recurrence for >10 years following starting the initial treatment for ER-positive/HER2 negative breast cancer, registered in 9 institutions, were analyzed. The distributions of TILs and their clinical relevance were investigated. TIL distributions did not differ significantly among the early, late and no recurrence groups, employing a 30% cut-off point as a dichotomous variable. In those who had received adjuvant chemotherapy as well as endocrine therapy, a trend toward higher TIL proportions was detected when the early recurrence group was compared with the no recurrence group employing the 30% cut-off point (P=0.064). The TIL distributions were significantly associated with nodal metastasis (P=0.004), ER status (P=0.045), progesterone receptor (PgR) status (P=0.002), tumor grade (P=0.021), and the Ki67 labeling index (LI) (P=0.002) in the no recurrence group and with the Ki67 LI in the recurrence groups (P=0.002 in early recurrence group, P=0.023 in late recurrence group). High TIL distributions also predicted shorter survival time following the detection of recurrence (P=0.026). However, these prognostic interactions were not significant in multivariate analysis (P=0.200). The present retrospective study demonstrated no significant interaction between TIL proportions and the timing of recurrence. However, higher TIL proportions were observed in breast cancer patients with aggressive biological phenotypes, which tended to be more responsive to chemotherapy. The clinical relevance of stromal TILs for identifying patients who would likely benefit from additional therapies merits further investigation in a larger patient population.
キーワード
breast cancer
estrogen receptor positive
human epidermal growth factor receptor type 2 negative
prognosis
tumor infiltrating lymphocytes
発行日
2018-12-19
出版物タイトル
Oncology Letters
17巻
2号
出版者
Spandidos Publications
開始ページ
2177
終了ページ
2186
ISSN
1792-1074
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
論文のバージョン
publisher
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.3892/ol.2018.9853
助成機関名
Japan Agency for Medical Research and Development
助成番号
17ck0106307h0001